Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Aptevo Therapeutics Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +1 vs. Q4 2021
- Shares held
- 811.9K
- +51.1K (+6.7%) vs. Q4 2021
- Total value
- $4.76M
- −$1.22M (−20.4%) vs. Q4 2021
- New holders
- 5
- 3 more added
- Sold out
- 4
- 6 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| US Bancorp | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 6 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 10 | $0 | 0.00% | 00.0% | Unchanged |
| Earnest Partners LLC | 14 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 30 | $0 | 0.00% | 00.0% | Unchanged |
| Money Concepts Capital Corp | 7 | $0 | 0.00% | +7 | New |
| The PNC Financial Services Group, Inc. | 142 | $1.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 204 | $1.00K | 0.00% | +204 | New |
| Fifth Third Bancorp | 291 | $2.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1,614 | $9.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,555 | $9.00K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 10,941 | $64.0K | 0.00% | −32−0.3% | Reduced |
| Franklin Resources Inc | 15,900 | $93.0K | 0.00% | +250+1.6% | Added |
| Northern Trust Corp | 16,695 | $98.0K | 0.00% | −5,869−26.0% | Reduced |
| Susquehanna International Group, LLP | 19,660 | $115.0K | 0.00% | +19,660 | New |
| Bank of New York Mellon Corp | 25,952 | $152.0K | 0.00% | +25,952 | New |
| Price T Rowe Associates Inc | 46,200 | $271.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 51,096 | $300.0K | 0.00% | −61,059−54.4% | Reduced |
| Geode Capital Management, LLC | 52,727 | $309.0K | 0.00% | +12,920+32.5% | Added |
| BlackRock Inc. | 54,367 | $319.0K | 0.00% | −306−0.6% | Reduced |
| Renaissance Technologies LLC | 58,886 | $346.0K | 0.00% | −9,800−14.3% | Reduced |
| Barclays PLC | 66,801 | $392.0K | 0.00% | +66,801 | New |
| Schonfeld Strategic Advisors LLC | 148,000 | $869.0K | 0.01% | −8,700−5.6% | Reduced |
| Vanguard Group Inc | 240,819 | $1.41M | 0.00% | +16,337+7.3% | Added |
| UBS Group AG | 0 | $0 | 0.00% | −3,212−100.0% | Sold out |
| ACT Capital Management, LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −95−100.0% | Sold out |